Data completeness
0/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORMIFLO (ardeparin sodium) is an injectable low-molecular-weight heparin (LMWH) anticoagulant in pre-launch development by Pfizer. The drug is indicated for thromboembolism prophylaxis and treatment in patients requiring anticoagulation. Ardeparin works by inhibiting thrombin and Factor Xa, preventing blood clot formation.
Pre-Launch
Pre-launch stage indicates team building and commercialization planning phases; career opportunity to join a product from inception through market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining NORMIFLO offers rare opportunity to build a product from pre-launch through commercialization within Pfizer's established infrastructure and anticoagulation franchise. This is ideal for professionals seeking launch experience, cross-functional collaboration, and career growth with a foundational therapeutic asset.
Brand ManagerCommercial Manager
Worked on NORMIFLO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.